跳至主要内容
临床试验/NCT03655015
NCT03655015
招募中
不适用

Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer (CTMS 18-0056)

The University of Texas Health Science Center at San Antonio2 个研究点 分布在 1 个国家目标入组 150 人2018年10月16日
适应症Lung Neoplasm

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Lung Neoplasm
发起方
The University of Texas Health Science Center at San Antonio
入组人数
150
试验地点
2
主要终点
To establish and characterize a biobank of patient-derived organoids (PDOs), and investigate the potential of PDOs to recapitulate ex vivo responses to chemotherapeutic and targeted agents observed in the clinic.
状态
招募中
最后更新
12天前

概览

简要总结

Create a living biobank of PDOs from Stage I-III lung cancer patients.

详细描述

Creation a living biobank of PDOs from Stage I-IV lung cancer patients (n=50). We selected enrollment of at least 50 patients so that they can be risk stratified based on lung tumor type, staging and we plan to store these PDOs in biobank for future experiments. For each patient, tumor specimens will be collected at time of their surgery. No specific therapeutic intervention or treatment is provided as part of this study. 1. Establishment and culture of PDOs from lung cancer tumor specimens. PDOs will be biobanked for future experiments. 2. Lung organoids and CTCs will also be cultured and used to study baseline tumor characteristics using histology, immunohistochemistry, atomic force measurements; as well as, oncogenic signaling pathways and proteomic profile of lung organoids and CTCs derived from lung cancer patients (n\>50). 3. Patient demographic information and data to be collected using a patient survey data sheet with treatment and survival history collected at pre-defined time period per the protocol schedule.

注册库
clinicaltrials.gov
开始日期
2018年10月16日
结束日期
2029年12月1日
最后更新
12天前
研究类型
Observational
性别
All

研究者

责任方
Principal Investigator
主要研究者

Josephine Taverna

Principal Investigator

The University of Texas Health Science Center at San Antonio

入排标准

入选标准

  • Read, consented to and signed the IRB-approved informed consent form prior to any study related procedure.
  • Diagnosis of lung cancer or lung mass or lymphadenopathy that will either systemic treatment or tumor resection as part of standard of care
  • Any clinical stage of lung cancer
  • Adult patients ≥18 years of age
  • Able and willing to complete a questionnaire on their environmental/occupational exposures and smoking/alcohol history

排除标准

  • At the discretion of the treating physician, patient will not be able to fulfill the requirements of the study.

结局指标

主要结局

To establish and characterize a biobank of patient-derived organoids (PDOs), and investigate the potential of PDOs to recapitulate ex vivo responses to chemotherapeutic and targeted agents observed in the clinic.

时间窗: 10 years

Establishment of a living biobank of PDOs and the potential of PDOs to repeat their process outside a living organism

次要结局

  • Correlation of PDO and Circulating tumor cells (CTCs)(10 years)

研究点 (2)

Loading locations...

相似试验